Oxcarbazepine (Epilepsy) updated on 04-22-2025

Low birth weight (< 2500g)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S16081
R66733		 Christensen (Oxcarbazepine) (Epilepsy) (Controls exposed to LTG), 2024 Low birth weight (<2500 g) during pregnancy (anytime or not specified) population based cohort retrospective exposed to other treatment, sick excluded Adjustment: No 1.12 [0.86;1.48] C
excluded (control group) 		71/1,462   230/5,299 301 1,462
ref
S16029
R66537		 Christensen (Oxcarbazepine) (Epilepsy) (Controls unexposed, general population), 2024 Low birth weight (<2500 g) during pregnancy (anytime or not specified) population based cohort retrospective unexposed, sick Adjustment: Yes 1.15 [0.86;1.54] 71/1,462   1,006/22,227 1,077 1,462
ref
S10096
R36755		 Coste (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2020 Weight at birth <2500 g during pregnancy (anytime or not specified) retrospective cohort (claims database) exposed to other treatment, sick excluded Adjustment: No Controls: mixed indications 1.40 [0.76;2.58] C
excluded (control group) 		12/143   179/2,916 191 143
ref
S7808
R23127		 Coste (Oxcarbazepine) (Controls unexposed, NOS), 2020 Weight at birth <2500 g during pregnancy (anytime or not specified) retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: No 1.62 [0.90;2.93] C 12/143   91,455/1,710,441 91,467 143
ref
Total 2 studies 1.24 [0.94;1.62] 92,544 1,605
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Christensen (Oxcarbazepine) (Epilepsy) (Controls unexposed, general population), 2024Christensen, 2024 1 1.15[0.86; 1.54]1,0771,46279%ROB confusion: seriousROB selection: lowROB classification: criticalROB missing: lowROB mesure: moderateROB reporting: moderate Coste (Oxcarbazepine) (Controls unexposed, NOS), 2020Coste, 2020 2 1.62[0.90; 2.93]91,46714321%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (2 studies) I2 = 4% 1.24[0.94; 1.62]92,5441,6050.55.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Oxcarbazepine) (Epilepsy) (Controls unexposed, general population; 2: Oxcarbazepine) (Controls unexposed, NOS;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.24[0.94; 1.62]92,5441,6054%NAChristensen (Oxcarbazepine) (Epilepsy) (Controls unexposed, general population), 2024 Coste (Oxcarbazepine) (Controls unexposed, NOS), 2020 2 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.62[0.90; 2.93]91,467143 -NACoste (Oxcarbazepine) (Controls unexposed, NOS), 2020 1 unexposed, sickunexposed, sick 1.15[0.86; 1.54]1,0771,462 -NAChristensen (Oxcarbazepine) (Epilepsy) (Controls unexposed, general population), 2024 1 Tags Adjustment   - No  - No 1.62[0.90; 2.93]91,467143 -NACoste (Oxcarbazepine) (Controls unexposed, NOS), 2020 1   - Yes  - Yes 1.15[0.86; 1.54]1,0771,462 -NAChristensen (Oxcarbazepine) (Epilepsy) (Controls unexposed, general population), 2024 1 All studiesAll studies 1.24[0.94; 1.62]92,5441,6054%NAChristensen (Oxcarbazepine) (Epilepsy) (Controls unexposed, general population), 2024 Coste (Oxcarbazepine) (Controls unexposed, NOS), 2020 20.55.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 10096, 16081

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.62[0.90; 2.93]91,467143 -NACoste (Oxcarbazepine) (Controls unexposed, NOS), 2020 1 unexposed, sick controlsunexposed, sick controls 1.15[0.86; 1.54]1,0771,462 -NAChristensen (Oxcarbazepine) (Epilepsy) (Controls unexposed, general population), 2024 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.17[0.91; 1.50]4921,6050%NAChristensen (Oxcarbazepine) (Epilepsy) (Controls exposed to LTG), 2024 Coste (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2020 20.510.01.0